Hippo Pathway in Cancer: Aberrant Regulation and Therapeutic Opportunities

被引:283
作者
Calses, Philamer C. [1 ,2 ]
Crawford, James J. [3 ]
Lill, Jennie R. [2 ]
Dey, Anwesha [1 ]
机构
[1] Genentech Inc, Dept Discovery Oncol, 1 DNA Way, San Francisco, CA 94080 USA
[2] Genentech Inc, Dept Microchem Prote & Lipid, 1 DNA Way, San Francisco, CA 94080 USA
[3] Genentech Inc, Dept Discovery Chem, 1 DNA Way, San Francisco, CA 94080 USA
来源
TRENDS IN CANCER | 2019年 / 5卷 / 05期
关键词
SQUAMOUS-CELL CARCINOMA; EFFECTOR YAP; ANTITUBULIN DRUGS; RESISTANCE; TEAD; ACTIVATION; YAP/TAZ; OVEREXPRESSION; SENSITIVITY; INHIBITION;
D O I
10.1016/j.trecan.2019.04.001
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The Hippo pathway remains a central focus in both basic and translational research and is a key modulator of developmental biology. Dysregulation of the pathway is associated with a plethora of human cancers and there are multiple efforts to target key components of the pathway for disease intervention. In this review, we briefly highlight the latest research advances around the core components of the Hippo pathway in cancer. More specifically, we discuss several genetic aberrations of these factors as mechanisms for the development of cancers, including genetic amplification, deletion, and gene fusions. Additionally, we highlight the role of the Hippo pathway in cancer therapy resistance and tumor immunogenicity. Last, we summarize the ongoing efforts to target the pathway in cancers.
引用
收藏
页码:297 / 307
页数:11
相关论文
共 70 条
  • [1] Novel YAP1-TFE3 fusion defines a distinct subset of epithelioid hemangioendothelioma
    Antonescu, Cristina R.
    Le Loarer, Francois
    Mosquera, Juan-Miguel
    Sboner, Andrea
    Zhang, Lei
    Chen, Chun-Liang
    Chen, Hsiao-Wei
    Pathan, Nursat
    Krausz, Thomas
    Dickson, Brendan C.
    Weinreb, Ilan
    Rubin, Mark A.
    Hameed, Meera
    Fletcher, Christopher D. M.
    [J]. GENES CHROMOSOMES & CANCER, 2013, 52 (08) : 775 - 784
  • [2] Barth M, Patent No. [WO2018185266, 2018185266]
  • [3] Barth M.C., Patent, Patent No. 2017064277
  • [4] Behnke D, Patent No. [WO2018198077A2, 2018198077]
  • [5] The clinically used photosensitizer Verteporfin (VP) inhibits YAP-TEAD and human retinoblastoma cell growth in vitro without light activation
    Brodowska, Katarzyna
    Al-Moujahed, Ahmad
    Marmalidou, Anna
    Horste, Melissa Meyer Zu
    Cichy, Joanna
    Miller, Joan W.
    Gragoudas, Evangelos
    Vavvas, Demetrios G.
    [J]. EXPERIMENTAL EYE RESEARCH, 2014, 124 : 67 - 73
  • [6] Bum-Erdene K, 2018, CELL CHEM BIOL, V26
  • [7] Chan P, 2016, NAT CHEM BIOL, V12, P282, DOI [10.1038/NCHEMBIO.2036, 10.1038/nchembio.2036]
  • [8] The Hippo Transducer TAZ Confers Cancer Stem Cell-Related Traits on Breast Cancer Cells
    Cordenonsi, Michelangelo
    Zanconato, Francesca
    Azzolin, Luca
    Forcato, Mattia
    Rosato, Antonio
    Frasson, Chiara
    Inui, Masafumi
    Montagner, Marco
    Parenti, Anna R.
    Poletti, Alessandro
    Daidone, Maria Grazia
    Dupont, Sirio
    Basso, Giuseppe
    Bicciato, Silvio
    Piccolo, Stefano
    [J]. CELL, 2011, 147 (04) : 759 - 772
  • [9] Hippo pathway inhibition by blocking the YAP/TAZ-TEAD interface: a patent review
    Crawford, James J.
    Bronner, Sarah M.
    Zbieg, Jason R.
    [J]. EXPERT OPINION ON THERAPEUTIC PATENTS, 2018, 28 (12) : 867 - 873
  • [10] Transcriptome meta-analysis of lung cancer reveals recurrent aberrations in NRG1 and Hippo pathway genes
    Dhanasekaran, Saravana M.
    Balbin, O. Alejandro
    Chen, Guoan
    Nadal, Ernest
    Kalyana-Sundaram, Shanker
    Pan, Jincheng
    Veeneman, Brendan
    Cao, Xuhong
    Malik, Rohit
    Vats, Pankaj
    Wang, Rui
    Huang, Stephanie
    Zhong, Jinjie
    Jing, Xiaojun
    Iyer, Matthew
    Wu, Yi-Mi
    Harms, Paul W.
    Lin, Jules
    Reddy, Rishindra
    Brennan, Christine
    Palanisamy, Nallasivam
    Chang, Andrew C.
    Truini, Anna
    Truini, Mauro
    Robinson, Dan R.
    Beer, David G.
    Chinnaiyan, Arul M.
    [J]. NATURE COMMUNICATIONS, 2014, 5